Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Updated BSH guidelines for managing DLBCL

Cathy Burton • 16 Feb 2024
CAR-T Meeting 2024
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Epcoritamab Glofitamab Polatuzumab vedotin R-CHP

Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James’s University Hospital, Leeds, UK, introduces the updated British Society for Hematology (BSH) guidelines for managing newly diagnosed large B-cell lymphoma (DLBCL). The guidelines encompass novel first-line therapies like Pola-R-CHP, second-line CAR-T therapies, and third-line bispecific antibodies. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Funded by Kite Gilead to attend meeting.

More from Cathy Burton

4:29
Improving survival outcomes and optimizing CAR-T therapy in patients with DLBCL
Cathy Burton • 16 Feb 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals